Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
1349 On Other Exchanges
Symbol
Exchange
1349 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

shanghai fudan-zhangjiang-h (1349) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SHANGHAI FUDAN-ZHANGJIANG-H (1349)

Related News

No related news articles were found.

shanghai fudan-zhangjiang-h (1349) Related Businessweek News

No Related Businessweek News Found

shanghai fudan-zhangjiang-h (1349) Details

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, is engaged in the research, development, manufacture, and sale of bio-pharmaceutical products in the People’s Republic of China. The company offers genetic engineering drugs, which include recombinant tissue type plasminogen activator for heart infarction; recombinant human lymphotoxin a-derivatives, a phase II clinical trial product for tumors; recombinant human tumor necrosis recipient Fc fusion protein (Etanercept) and high bio-activity recombinant human TNF receptor for the treatment of arthritis; PTH that is in phase I clinical trial product for osteoporosis; CD30-MMAE and Avastin, which are in pre-clinical study for treating tumor; Anti-sclerostin mab that is in pre-clinical study for the treatment of Osteoporosis; and PCSK9, which is in pre-clinical study for hypercholesterolemia. It also provides photodynamic therapy drugs comprising Hemoporfin for the treatment of port wine stain; Duteroporphyrin, a phase I clinical trial product for treating tumors; and Aminolevulinic acid that is in phase I clinical trial for the treatment of cervical diseases infected by HPV, as well as in pre-clinical study for treating acne, brain gliomas, and basal cell carcinoma diseases. In addition, the company offers liposomal drugs, including Libod, a doxorubicin liposome injection for treating tumors; Vincristine sulphate liposome, which is in phase–I clinical trial for treating tumors; Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical study for the treatment of tumors; and Xenon liposome, which is in pre-clinical study for treating strokes. Further, it provides Antenatal Screening Diagnostic Reagent for down’s syndrome; and Nifeviroc that is in research for AIDS prevention, as well as sells medical diagnostic products. It has a strategic agreement with Shanghai Pharmaceutical Co., Ltd. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.

498 Employees
Last Reported Date: 03/24/15
Founded in 1996

shanghai fudan-zhangjiang-h (1349) Top Compensated Officers

Co-Founder, Chairman, General Manager and Cha...
Total Annual Compensation: CNY2.0M
Co-Founder, Deputy General Manager and Execut...
Total Annual Compensation: CNY1.2M
Deputy General Manager and Executive Director
Total Annual Compensation: CNY1.2M
Compensation as of Fiscal Year 2013.

shanghai fudan-zhangjiang-h (1349) Key Developments

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. Reports Consolidated Earnings Results for the Year Ended December 31, 2014

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. reported consolidated earnings results for the year ended December 31, 2014. For the period, revenue was RMB 470.900 million against RMB 415.925 million a year ago. Operating profit was RMB 129.960 million against RMB 108.360 million a year ago. Profit before income tax was RMB 128.099 million against RMB 98.946 million a year ago. Profit attributable to shareholders of the company was RMB 118.258 million or RMB 0.1281 per basic and diluted share against RMB 87.218 million or RMB 0.1009 per basic and diluted share a year ago. EBITDA was RMB 155.748 million compared to RMB 124.212 million a year ago.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Recommends Final Dividend for the Year Ended December 31, 2014, Payable on July 27, 2015

On March 24, 2015, the Board of Directors of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. recommended the payment of a final dividend of RMB 0.05 per ordinary share, totaling RMB 46,150,000 for the year ended December 31, 2014 compared to nil dividend in 2013. If the profit distribution plan is approved by the shareholders by way of an ordinary resolution at the 2014 annual general meeting to be held on May 29, 2015, the final dividend is expected to be distributed on July 27, 2015 to holders whose names appear on the register of the company on June 11, 2015.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Announces Board Changes

The board of directors of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. announced on 24 March 2015 that Mr. Chen Kai Xian has tendered resignation as an independent non-executive Director of the fifth session of the Board due to personal reason; Mr. Zhao Wen Bin has tendered resignation as a supervisor of the fifth session of the supervisory committee of the company due to work reallocation arranged by his employer; and Mr. Xu Qing has tendered resignation as a Supervisor because he has been nominated as an independent non-executive Director of the fifth session of the Board. Such resignations have been accepted by the Board upon discussions and will become effective after the conclusion of the forthcoming 2014 annual general meeting of the company. Each of Mr. Chen, Mr. Zhao and Mr. Xu has confirmed that he does not have any disagreement with the company and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the company or The Stock Exchange of Hong Kong Limited. The Board also announced that it proposes to appoint Mr. Xu Qing as an independent non-executive Director of the fifth session of the Board; Mr. Zhou Xi as a Supervisor of the fifth session of the Supervisory Committee. Mr. Xu Qing was appointed as an independent supervisor in May 2008. He is currently a professor of Tongji Unversity Medical School, doctor-postgraduate supervisor, deputy director of the Oncology Department and Tumor Institute, and director, chief physician of Medical Oncology Department of the Tenth People’s Hospital affiliated to Tongji University. And he is director of Medical Oncology Department of Shanghai Dermatology Hospital affiliated to Tongji University. Zhou Xi is the general manager of Shanghai Fudan Asset Management Co. Ltd. He used to be the deputy secretary of youth communist league committee of Fudan University, assistant to director of the Enterprise Incubation and Equity Management Office of Fudan University, deputy director of Jiangwan campus construction office of Fudan University, vice president of School of Computer Science and Software School of Fudan University.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
1349:HK $7.42 HKD +0.10

1349 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 1349.
View Industry Companies
 

Industry Analysis

1349

Industry Average

Valuation 1349 Industry Range
Price/Earnings 45.7x
Price/Sales 11.5x
Price/Book 8.3x
Price/Cash Flow 45.7x
TEV/Sales 10.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHANGHAI FUDAN-ZHANGJIANG-H, please visit www.fd-zj.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.